Publication:
Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial

dc.bibliographiccitation.firstpage2296
dc.bibliographiccitation.issue9
dc.bibliographiccitation.journalBiomedicines
dc.bibliographiccitation.volume10
dc.contributor.affiliationLechner, Katharina; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany
dc.contributor.affiliationvon Schacky, Clemens; 4Omegametrix, Martinsried, 82152 Munich, Germany
dc.contributor.affiliationScherr, Johannes; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany
dc.contributor.affiliationLorenz, Elke; 3Kardiologie, Deutsches Herzzentrum München, 80636 Munich, Germany
dc.contributor.affiliationBock, Matthias; 2DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance, 80336 Munich, Germany
dc.contributor.affiliationLechner, Benjamin; 6Department of Internal Medicine IV, Ludwig-Maximilians University, 80336 Munich, Germany
dc.contributor.affiliationHaller, Bernhard; 7Institute of AI and Informatics in Medicine, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
dc.contributor.affiliationKrannich, Alexander; 8Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany
dc.contributor.affiliationHalle, Martin; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany
dc.contributor.affiliationWachter, Rolf; 9Clinic and Policlinic for Cardiology, University Hospital Leipzig, 04103 Leipzig, Germany
dc.contributor.affiliationDuvinage, André; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany
dc.contributor.affiliationEdelmann, Frank; 12Department of Cardiology, Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany
dc.contributor.authorLechner, Katharina
dc.contributor.authorvon Schacky, Clemens
dc.contributor.authorScherr, Johannes
dc.contributor.authorLorenz, Elke
dc.contributor.authorBock, Matthias
dc.contributor.authorLechner, Benjamin
dc.contributor.authorHaller, Bernhard
dc.contributor.authorKrannich, Alexander
dc.contributor.authorHalle, Martin
dc.contributor.authorWachter, Rolf
dc.contributor.authorEdelmann, Frank
dc.contributor.authorDuvinage, André
dc.date.accessioned2022-10-04T10:21:47Z
dc.date.available2022-10-04T10:21:47Z
dc.date.issued2022
dc.date.updated2022-11-11T13:13:12Z
dc.description.abstractBackground: Circulating long-chain (LCSFAs) and very long-chain saturated fatty acids (VLSFAs) have been differentially linked to risk of incident heart failure (HF). In patients with heart failure with preserved ejection fraction (HFpEF), associations of blood SFA levels with patient characteristics are unknown. Methods: From the Aldo-DHF-RCT, whole blood SFAs were analyzed at baseline in n = 404 using the HS-Omega-3-Index® methodology. Patient characteristics were 67 ± 8 years, 53% female, NYHA II/III (87%/13%), ejection fraction ≥50%, E/e’ 7.1 ± 1.5; and median NT-proBNP 158 ng/L (IQR 82–298). Spearman´s correlation coefficients and linear regression analyses, using sex and age as covariates, were used to describe associations of blood SFAs with metabolic phenotype, functional capacity, cardiac function, and neurohumoral activation at baseline and after 12-month follow-up (12 mFU). Results: In line with prior data supporting a potential role of de novo lipogenesis-related LCSFAs in the development of HF, we showed that baseline blood levels of C14:0 and C16:0 were associated with cardiovascular risk factors and/or lower exercise capacity in patients with HFpEF at baseline/12 mFU. Contrarily, the three major circulating VLSFAs, lignoceric acid (C24:0), behenic acid (C22:0), and arachidic acid (C20:0), as well as the LCSFA C18:0, were broadly associated with a lower risk phenotype, particularly a lower risk lipid profile. No associations were found between cardiac function and blood SFAs. Conclusions: Blood SFAs were differentially linked to biomarkers and anthropometric markers indicative of a higher-/lower-risk cardiometabolic phenotype in HFpEF patients. Blood SFA warrant further investigation as prognostic markers in HFpEF. One Sentence Summary: In patients with HFpEF, individual circulating blood SFAs were differentially associated with cardiometabolic phenotype and aerobic capacity.
dc.description.sponsorshipGerman Foundation of Heart Research
dc.description.sponsorshipFederal Ministry of Education and research
dc.identifier.doi10.3390/biomedicines10092296
dc.identifier.piibiomedicines10092296
dc.identifier.urihttps://resolver.sub.uni-goettingen.de/purl?gro-2/114500
dc.item.fulltextWith Fulltext
dc.language.isoen
dc.notes.internDOI-Import GROB-600
dc.relation.eissn2227-9059
dc.relation.orgunitKlinik für Kardiologie und Pneumologie
dc.relation.orgunitUniversitätsmedizin Göttingen
dc.relation.orgunitDeutsches Zentrum für Herz-Kreislauf-Forschung e.V.
dc.rightsCC BY 4.0
dc.titleSaturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial
dc.typejournal_article
dc.type.internalPublicationyes
dc.type.versionpublished_version
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
biomedicines-10-02296-v3.pdf
Size:
2.3 MB
Format:
Unknown data format

Collections